5:38 PM
 | 
Oct 08, 2012
 |  BC Extra  |  Company News

Optimer selling stake in Taiwan subsidiary for $60M

Optimer Pharmaceuticals Inc. (NASDAQ:OPTR) plans to sell its 43.6% stake in Taiwan subsidiary Optimer Biotechnology Inc. to the subsidiary's other shareholders for $60 million. Optimer Biotechnology is conducting a Phase II/III trial of OPT-822/821 to treat metastatic breast cancer. The subsidiary has rights from...

Read the full 205 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >